Literature DB >> 22965292

Failure of pentagastrin-stimulated calcitonin testing in early manifestation of familial medullary thyroid cancer.

Christian Pirich1, Gundula Rendl, Cornelia Hauser-Kronberger, Ingrid Häusler.   

Abstract

This case report describes three generations of a family with familial medullary thyroid cancer (RET gene mutation L790F). One of the three siblings-all of them carrier of the respective mutation-exhibited the absence of pathological basal and pentagastrin-stimulated calcitonin levels in spite of multifocal medullary thyroid microcancer. This case illustrates the challenge to consider the biological diversity of RET gene mutations in the clinical management of affected gene carriers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965292     DOI: 10.1007/s00508-012-0241-y

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  3 in total

1.  The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center.

Authors:  Rossella Elisei; Cristina Romei; Giulia Renzini; Valeria Bottici; Barbara Cosci; Eleonora Molinaro; Laura Agate; Virginia Cappagli; Paolo Miccoli; Piero Berti; Pinuccia Faviana; Clara Ugolini; Fulvio Basolo; Paolo Vitti; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2011-12-07       Impact factor: 5.958

2.  Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.

Authors:  Karin Frank-Raue; Andreas Machens; Christian Scheuba; Bruno Niederle; Henning Dralle; Friedhelm Raue
Journal:  Clin Endocrinol (Oxf)       Date:  2008-02-03       Impact factor: 3.478

3.  Sensitive calcitonin measurement by two-site immunometric assays: implications for calcitonin screening in nodular thyroid disease.

Authors:  Bernhard Saller; Rainer Görges; Walter Reinhardt; Katharina Haupt; Onno E Janssen; Klaus Mann
Journal:  Clin Lab       Date:  2002       Impact factor: 1.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.